Compare Incyte Corporation (INCY) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares Semiconductor ETF — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while iShares Semiconductor ETF trades at $546. The key difference: Incyte Corporation is trading nearer its 52-week high, iShares Semiconductor ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SOXX | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Sector/Thematic |
52-Week High | $118.52 | $655.01 |
52-Week Low | $67.38 | $236.93 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SOXX, the iShares Semiconductor ETF, trades at $524.14, up 0.45% on the day but down 20% from its June 2026 all-time high, reflecting a sector-wide correction. Technical indicators are bearish, with the ETF facing resistance near $533. Recent news highlights a sharp pullback in semiconductor stocks amid concerns over AI-driven valuations and cyclical pressures, though long-term demand drivers remain intact.
The outlook for SOXX is cautious near-term due to technical weakness and sentiment headwinds, but the ETF's concentrated exposure to leading chipmakers offers growth potential if AI and memory demand persist. Key risks include sector volatility, valuation concerns, and macroeconomic shifts impacting tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
